title: HER2 Intermediate Breast Cancers.
authors.forename: Kristin C
authors.initials: KC
authors.lastname: Jensen
authors.forename: Torsten O
authors.initials: TO
authors.lastname: Nielsen
authors.forename: C Blake
authors.initials: CB
authors.lastname: Gilks
authors.forename: Robert B
authors.initials: RB
authors.lastname: West
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000235:genetics / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D018628:Gene Dosage; D017408:Guidelines as Topic; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000037:antagonists & inhibitors; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human